34 completed, 23 recruiting, 21 active not recruiting, 17 terminated. 105 Phase 2, 9 Phase 1, 2 Phase 3.
Follow Prostate Adenocarcinoma: new trials by email Literature Review of Prostate Adenocarcinoma trials Research Report on Prostate Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Whole Versus Partial Gland Boost During Prostate SBRT Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Not yet recruiting | University of Nebraska | 160 | 2026-12-25 | 2026-11-03 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer Radiation therapy - Prostate Adenocarcinoma | Phase 2 | Recruiting | University of California, San Diego | 150 | 2026-07-20 | 2026-08-04 |
| A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer Exercise Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 102 | 2026-07-13 | 2026-10-30 |
| A Study of Lower Dose Radiation Therapy for People With Prostate Cancer MR-guided Stereotactic Body Radiation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2026-05-28 | 2026-06-18 |
| Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) Recurrence-directed therapy (RDT), ELIGARD 22.5mg - Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 162 | 2026-05-06 | 2026-10-13 |
| Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation Flotufolastat F18 PET - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Not yet recruiting | University of California, Irvine | 60 | 2026-05-01 | 2026-05-06 |
| INSPIRE: INnovative SABR for Prostate Cancer All IREland Next generation Stereotactic Ablative Radiotherapy (SABR) - Prostate Adenocarcinoma | Phase 2 | Recruiting | Cancer Trials Ireland | 136 | 2026-04-23 | 2026-07-06 |
| Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18 - Prostatic Neoplasms, Prostate Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 120 | 2026-02-10 | 2026-02-23 |
| Neoadjuvant Embolization and Cytoreduction in Prostate Cancer Prostatic Artery Embolization - Prostate Adenocarcinoma | Phase 2 | Not yet recruiting | Srinivas Raman | 35 | 2026-02-01 | 2025-11-26 |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | Shehzad Basaria, M.D. | 60 | 2026-01-14 | 2026-08-17 |
| Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 30 | 2025-08-25 | 2026-09-23 |
| Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy Lu-17-PSMA-617 - Prostate Adenocarcinoma | Phase 2 | Recruiting | Hackensack Meridian Health | 54 | 2025-03-05 | 2026-03-23 |
| EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | University of Virginia | 60 | 2025-01-30 | 2026-04-27 |
| A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Relacorilant, Enzalutamide, Placebo (Sugar Pill) - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Chicago | 90 | 2025-01-06 | 2026-08-31 |
| Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial Biopsy Procedure, Biospecimen Collection, Placebo Administration - Prostate Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 90 | 2024-09-12 | 2026-10-27 |
| Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial Biopsy, Biospecimen Collection, Computed Tomography - Prostate Adenocarcinoma | Phase 2 | Recruiting | Sean Sachdev | 50 | 2024-09-06 | 2026-10-30 |
| Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer Biospecimen Collection, Contrast Agent, Leuprolide - Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 70 | 2024-08-12 | 2026-03-09 |
| PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Miami | 34 | 2024-07-03 | 2026-06-16 |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 8 | 2024-05-23 | 2026-10-19 |
Showing 20 of 105. Sign in to see all of them.
Prostatic Neoplasms (74) · Adenocarcinoma Of Esophagus (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Anus Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Erectile Dysfunction (1) · Fasting (1) · Genital Neoplasms, Male (1)
Genital Diseases (76) · Male Urogenital Diseases (76) · Neoplasms (76) · Neoplasms by Site (76) · Urogenital Diseases (76) · Genital Diseases, Male (75) · Prostatic Diseases (74) · Urogenital Neoplasms (74) · Genital Neoplasms, Male (73) · Pathological Conditions, Signs and Symptoms (6) · Neoplastic Processes (3) · Pathologic Processes (3) · Signs and Symptoms (3) · Breast Diseases (2) · Breast Neoplasms (2)
Magnetic Resonance Spectroscopy (19) · Leuprolide (13) · Specimen Handling (13) · Goserelin (10) · luprolide acetate gel depot (10) · Abiraterone Acetate (9) · Androgen Antagonists (9) · Prednisone (8) · apalutamide (7) · Radiosurgery (6) · X-Rays (6) · enzalutamide (6) · gallium 68 PSMA-11 (6) · Docetaxel (5) · Glutamate Carboxypeptidase II (5)
National Cancer Institute (NCI) (10) · University of Washington (9) · M.D. Anderson Cancer Center (8) · Mayo Clinic (7) · Jonsson Comprehensive Cancer Center (4) · Andrei Iagaru (3) · City of Hope Medical Center (3) · Memorial Sloan Kettering Cancer Center (3) · University of California, San Francisco (3) · University of Utah (3) · Emory University (2) · NRG Oncology (2) · Ohio State University Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)
United States (91) · Canada (7) · France (3) · Belgium (1) · Brazil (1) · Cyprus (1) · Ireland (1) · Netherlands (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Michael Schweizer (4) · Christopher Logothetis (3) · Amar Kishan (2) · Andrei Iagaru (2) · Carlos E. Vargas, M.D. (2) · Evan Yu (2) · Paul Corn (2) · Rahul Aggarwal, MD (2) · Alejandro Sanchez (1) · Amar Kishan, MD (1) · Andrei Iagaru, MD (1) · Andrew A Loblaw (1) · Andrew McDonald, MD (1) · Ashesh Jani, MD, MSEE (1)
PMID 15683820, PMID 20818327, PMID 25847934, PMID 29876010, PMID 30700328, PMID 30811282, PMID 31478089, PMID 31515154, PMID 33602654, PMID 33674398, PMID 34326126, PMID 34406051, PMID 34663638, PMID 35277461, PMID 36200668, PMID 37178932, PMID 37419394, PMID 37555901, PMID 37619656, PMID 38423030, PMID 38664016, PMID 39074346, PMID 39390760, PMID 39848765, PMID 40906325, PMID 41202201, PMID 41223345, PMID 41378786, PMID 41467749, PMID 41698328, PMID 42377125, PMID 8892467
P30CA008748 (2), P30CA015083 (2), P30CA015704 (2), P30CA016672 (2), P30CA060553 (2), P30CA138292 (2), U01CA062491 (2), U10CA180868 (2), 2018 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00100 (1), N01CM62202 (1), N01CM62205 (1)